MorphoSys’ (MOR) Buy Rating Reiterated at Deutsche Bank Aktiengesellschaft

MorphoSys (NASDAQ:MOR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Thursday, The Fly reports.

MOR has been the subject of a number of other reports. Berenberg Bank reaffirmed a “buy” rating on shares of MorphoSys in a research note on Monday, December 21st. SVB Leerink reiterated a “market perform” rating on shares of MorphoSys in a research note on Monday, March 29th. Morgan Stanley reissued an “equal weight” rating on shares of MorphoSys in a research note on Monday, March 29th. Finally, Zacks Investment Research downgraded shares of MorphoSys from a “hold” rating to a “sell” rating in a research note on Wednesday, March 24th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. MorphoSys presently has a consensus rating of “Hold” and a consensus price target of $38.00.

Get MorphoSys alerts:

MOR stock traded up $0.02 during mid-day trading on Thursday, hitting $22.18. 130 shares of the company were exchanged, compared to its average volume of 65,854. The business has a fifty day simple moving average of $24.15 and a 200-day simple moving average of $27.31. The firm has a market capitalization of $2.92 billion, a P/E ratio of 105.62 and a beta of 1.03. MorphoSys has a 12-month low of $21.27 and a 12-month high of $35.73.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MOR. Capital Asset Advisory Services LLC purchased a new position in shares of MorphoSys in the 4th quarter valued at $233,000. JPMorgan Chase & Co. boosted its stake in MorphoSys by 1,179.7% in the fourth quarter. JPMorgan Chase & Co. now owns 3,404 shares of the company’s stock valued at $97,000 after acquiring an additional 3,138 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of MorphoSys during the fourth quarter worth about $868,000. Vident Investment Advisory LLC grew its holdings in shares of MorphoSys by 35.4% during the fourth quarter. Vident Investment Advisory LLC now owns 58,814 shares of the company’s stock worth $1,667,000 after purchasing an additional 15,384 shares during the last quarter. Finally, OneAscent Wealth Management LLC purchased a new stake in shares of MorphoSys in the fourth quarter valued at about $264,000. Institutional investors and hedge funds own 3.06% of the company’s stock.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.

Further Reading: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.